Patients recruited to the study
Patient . | Age, y/sex . | History of aplastic anemia* . | Thrombosis . | Hemoglobin level, g/dL . | Reticulocyte count, % . | WBC count, × 109/L . | Platelet count, × 109/L . | % PNH III red blood cells† . | % PNH II red blood cells‡ . | % PNH polymorphonuclear leukocytes† . | Treatment . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 29/F | Yes | No | 5.4 | 2.6 | 2.5 | 19 | 20 | 5 | 70 | ATG |
| 2 | 51/M | Yes | No | 9.7 | — | — | 100 | 9 | 24 | 74 | ATG/CSA |
| 3 | 40/F | No | Yes | 12.4 | 2.2 | 4.2 | 74 | 6 | 6 | 52 | Enoxaparin |
| 4 | 74/M | No | No | 9.9 | 8.1 | 3.4 | 92 | 34 | 9 | 84 | Transfusion |
| 5 | 33/F | No | No | 9.4 | 20.2 | 3.7 | 263 | 28 | 24 | 83 | Transfusion |
Patient . | Age, y/sex . | History of aplastic anemia* . | Thrombosis . | Hemoglobin level, g/dL . | Reticulocyte count, % . | WBC count, × 109/L . | Platelet count, × 109/L . | % PNH III red blood cells† . | % PNH II red blood cells‡ . | % PNH polymorphonuclear leukocytes† . | Treatment . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 29/F | Yes | No | 5.4 | 2.6 | 2.5 | 19 | 20 | 5 | 70 | ATG |
| 2 | 51/M | Yes | No | 9.7 | — | — | 100 | 9 | 24 | 74 | ATG/CSA |
| 3 | 40/F | No | Yes | 12.4 | 2.2 | 4.2 | 74 | 6 | 6 | 52 | Enoxaparin |
| 4 | 74/M | No | No | 9.9 | 8.1 | 3.4 | 92 | 34 | 9 | 84 | Transfusion |
| 5 | 33/F | No | No | 9.4 | 20.2 | 3.7 | 263 | 28 | 24 | 83 | Transfusion |
To convert hemoglobin level from grams per deciliter to grams per liter, multiply grams per deciliter by 10.
ATG indicates equine antithymocyte globulin; WBC, white blood cell; CSA, cyclosporine; and —, not available.
Prior or concurrent history of clinically recognized aplastic anemia.
Fraction of PNH red cells and granulocytes was performed as previously described.25
Red cells with a partial deficiency in CD59 expression.4